Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海现代制药股份有限公司是一家以原料药和制剂的生产为主业的医药企业.公司产品覆盖原料药和制剂、药物新型制剂和生物药品三大领域,主导产品包括阿奇霉素、硫辛酸、头孢氨苄缓释胶囊、硝苯地平控释片和人尿制品等.公司是国内颇具优势的缓释药技术产品生产厂家,生产的头孢氨苄缓释胶囊销量占国内同类产品市场的一半份额以上,独家生产的硝苯地平控释片广泛用于治疗高血压和心绞痛,知名度较高.公司在产品种约20个,而储备品种数目也已达到20多个,具有较为丰富的储备品种资源.荣誉申报提升品牌内功,"现代"是上海市著名商标、"欣然"申报上海市著名商标的申请已被受理,4个产品已成为上海市名牌产品[现代(马来酸依那普利片)、现代(硫辛酸原料)、欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)],4个产品成为自主创新品牌[现代(马来酸依那普利片)、欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)、浦乐齐(阿奇霉素片)],5个产品成为上海市名优产品[欣然(硝苯地平控释片)、申嘉(头孢氨苄缓释胶囊)、申洛(头孢克洛缓释胶囊)、申嘉(头孢氨苄缓释胶囊)、现代(马来酸依那普利片)]。
Main Business 医药中间体和原料药以及新型制剂类药物的研发、生产和销售
Legal Representative 许继辉
Top Executives
董事长：许继辉
副董事长：刘勇
董事：李茹,王鹏,刘勇,魏树源
独立董事：吴范宏,李颖琦,田侃
Top 5 Shareholder
Shareholder name Nature Holding Date
上海医药工业研究院有限公司流通A股17.86%30/09/2024
中国医药投资有限公司流通A股12.97%30/09/2024
国药集团一致药业股份有限公司流通A股12.46%30/09/2024
中国医药集团有限公司流通A股11.41%30/09/2024
香港中央结算有限公司流通A股3.35%30/09/2024
Company Secretary 张忠喜
Solicitors 国浩律师（北京）事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 021-52372865
Fax No 021-58480136
Website www.shyndec.com
Email shyndec@sinopharm.com
Company Address
Register: 上海市浦东新区建陆路378号
Office: 上海市浦东新区建陆路378号
Listing Date 16/06/2004
Shares Capital
Shares Capital: 1,341,172,692
Total A Share: 1,341,172,692
Listed A Share: 1,341,172,692
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.543
DPS(RMB)* ¥ 0.100
NBV Per Share(RMB)* ¥ 9.237
Market Capitalization(RMB) 16.094B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.